This area is reserved for registered users. Please register or login.

Symbicort Turbohaler – Expanded Indication for Asthma in Adolescents

AstraZeneca Pharmaceuticals (Ireland) DAC is pleased to announce that Symbicort Turbohaler (budesonide/ formoterol fumarate dihydrate) inhalation powder in 100/6mcg & 200/6mcg strengths have received approval for use as maintenance and reliever therapy for asthma in adolescents (aged 12 to 17 years). Budesonide/ formoterol fumarate dihydrate is a combination corticosteroid/ selective long acting b2-agonist. The 100/6mcg strength is already approved for maintenance treatment of asthma in patients ≥6 years, and as maintenance and reliever therapy in adults. The 100/6mcg strength is not suitable for severe asthma. The 200/6mcg strength is also approved as maintenance and reliever therapy for asthma in adults.…